Publication:
Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer

dc.contributor.authorGoktas Aydin S.
dc.contributor.authorCakan Demirel B.
dc.contributor.authorBilici A.
dc.contributor.authorTOPÇU A.
dc.contributor.authorAykan M. B.
dc.contributor.authorKAHRAMAN S.
dc.contributor.authorAKBIYIK I.
dc.contributor.authorAtci M. M.
dc.contributor.authorOlmez O. F.
dc.contributor.authorYaren A.
dc.contributor.authoret al.
dc.contributor.institutionauthorTOPÇU, ATAKAN
dc.contributor.institutionauthorŞEKER, MESUT
dc.date.accessioned2023-01-08T22:59:59Z
dc.date.available2023-01-08T22:59:59Z
dc.date.issued2022-01-01
dc.description.abstract© 2022 Informa UK Limited, trading as Taylor & Francis Group.Objectives: Advanced-stage biliary tract cancers (BTC) are rare malignancies with poor prognosis. There are few prospective trials, but several retrospective studies regarding treatment options. In this study, we aimed to investigate the role of systemic inflammatory parameters (SIP) and other possible independent factors that may affect survival and treatment approaches and to determine the benefit of later-line treatments in these patients. Methods: A total of 284 patients, initially diagnosed with advanced stage or progressed after curative treatment of BTC, from different oncology centers in Turkey were included in this retrospective study. The prognostic significance of clinicopathological factors, SIPs and treatment options was analyzed. Results: At a median follow-up of 13 months, the median progression-free survival (PFS) was 6.1 months (95% CI:5.51–6.82), and the median overall survival (OS) time was 16.8 months (95% CI: 13.9–19.6). Treatment choice (p <.001 HR:0.70 CI95% 0.55–0.9), performance status (p <.001 HR:2.74 CI 95% 2.12–3.54) and neutrophil-to-lymphocyte ratio (NLR) (p =.02 HR:1.38 CI 95% 1.03–1.84) were independent prognostic factors for PFS. For OS, the independent prognostic indicators were determined as The Eastern Cooperative Oncology Group Performance Status (ECOG PS) (p <.001 HR:1.78 CI 95% 1.5–2.3), Systemic Immune-inflammation Index (SII) (p <.001 HR:0.51 CI95% 0.36–0.73) and stage at diagnosis (p =.002 HR:1.79 CI 95% 1.24–2.59). Furthermore, second and third line treatments significantly prolonged OS in advanced BTC (p <.001 HR:0.55 CI 95% 0.38–0.79; p =.007 HR:0.51 CI95% 0.31–0.83, respectively). Conclusion: SII and NLR are useful prognostic factors and may be helpful in making treatment decisions. Additionally, second and later-line treatments in advanced BTC have a significant impact on survival under real-life conditions.
dc.identifier.citationGoktas Aydin S., Cakan Demirel B., Bilici A., TOPÇU A., Aykan M. B., KAHRAMAN S., AKBIYIK I., Atci M. M., Olmez O. F., Yaren A., et al., "Real-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer", Current Medical Research and Opinion, cilt.38, sa.10, ss.1751-1758, 2022
dc.identifier.doi10.1080/03007995.2022.2108619
dc.identifier.endpage1758
dc.identifier.issn0300-7995
dc.identifier.issue10
dc.identifier.pubmed35916475
dc.identifier.scopus85136162860
dc.identifier.startpage1751
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85136162860&origin=inward
dc.identifier.urihttps://hdl.handle.net/20.500.12645/34931
dc.identifier.volume38
dc.identifier.wosWOS:000841144000001
dc.relation.ispartofCurrent Medical Research and Opinion
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectFundamental Medical Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, GENEL & DAHİLİ
dc.subjectClinical Medicine (MED)
dc.subjectCLINICAL MEDICINE
dc.subjectMEDICINE, GENERAL & INTERNAL
dc.subjectGenel Tıp
dc.subjectGeneral Medicine
dc.subjectbest supportive care
dc.subjectBiliary tract cancer
dc.subjectNLR
dc.subjectsecond-line chemotherapy
dc.subjectSII
dc.titleReal-life analysis of treatment approaches and the role of inflammatory markers on survival in patients with advanced biliary tract cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.idfed7fd46-9783-4719-be56-3b09876d3768
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
relation.isAuthorOfPublication37a739cd-75b5-4624-8d1e-a5d172edba69
relation.isAuthorOfPublication8a03684e-e421-4a9f-9069-168fc121a5d4
relation.isAuthorOfPublication.latestForDiscovery37a739cd-75b5-4624-8d1e-a5d172edba69
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c

Files